Study Shows: Omicron is Largely Resistant to These Two Conditions

Study Shows: Omicron is Largely Resistant to These Two Conditions
Coronavirus variant/courtesy

BERLIN – According to a new study, the new coronavirus variant Omicron is highly resistant to antibodies from people who have recovered from the virus and those who have received two doses of the Pfizer vaccine.

The study comes amid an increase in cases of the disease, as defined by the World Health Organization (WHO).

However, when combined with Pfizer and AstraZeneca, a third dose of the Pfizer vaccine may be effective against the new variant, according to the study.

Multiple antibodies previously used to treat Covid-19 have been found to be ineffective against Omicron, according to the study published in the journal Cell.

The Omicron coronavirus variant has caused widespread concern due to its high potential for transmission and the possibility of thirty-seven different mutations.

The variant was first discovered in South Africa and has since spread to over a hundred countries around the world.

According to the researchers, the Omicron variant of SARS-CoV-2 appears to be spreading faster than any previous variant and may soon dominate globally.

They used non-hazardous virus-like particles that carry the Omicron spike protein and are well suited to studying virus entry and inhibition in this study.

The SARS-CoV-2 virus uses the spike protein to enter and infect cells.

COVID-19 is currently treated with antibodies Casirivimab and Imdevimab, as well as Etesevimab and Bamlanivimab.

These antibodies, however, were found to be largely ineffective against the Omicron spike, according to the researchers. According to them, only one antibody, Sotrovimab, inhibited the Omicron spike.

Read more:

According to study first author Markus Hoffmann of the German Primate Center, “our cell culture studies suggest that most antibodies currently available for COVID-19 therapy will be ineffective against Omicron.”

“Sotrovimab is an exception,” Hoffmann said, adding that it “could become an important treatment option for Omicron-infected patients.”

Patients infected in Germany during the first wave of the pandemic may have produced antibodies that protect against the Omicron variant, according to the researchers.

While the antibodies were effective against the virus that caused the first wave, they were ineffective against the Omicron spike.

They believe these people don’t have strong immune defenses against the Omicron variant, though they haven’t looked into whether T cells, which are also produced during infection, play a role.

Antibodies produced after two doses of the Pfizer vaccine also inhibited the Omicron spike less effectively than spike proteins from other variants, according to the researchers.

They found that after three Pfizer doses and heterologous immunization with AstraZeneca and Pfizer preventives, there was a better protective effect.

According to the study, these findings suggest that dual immunization with Pfizer may provide less protection against the Omicron variant than the Delta variant.

It was discovered that triple immunization with Pfizer (booster) and cross-vaccination with AstraZeneca/Pfizer could provide better protection.

“Our findings suggest that Covid-19 antibody therapies should be tailored to the Omicron variant. The BioNTech-Pfizer vaccine should also be considered for adaptation “Hoffmann stated.

“In contrast, BioNTech-Pfizer (booster) triple immunization and cross-vaccination with Oxford-AstraZeneca,” Hoffmann said.

Have a tip we should know?

Most Read

  1. ARTS
    With a Vengeance and no Apologies, Art Basel Miami Beach Has Returned
    6 months ago
  2. Food
    Is Faux Turkey Finally Vegan-Approved for Thanksgiving?
    6 months ago
  3. News
    Pandora Papers Financial Leak Shows Us the Secrets of the World’s Rich and Powerful
    8 months ago
  4. Health
    US Supreme Court Rejects J & J TALC Cancer Case Appeal
    12 months ago
  5. Lifestyle
    9 Habits that Drain your Daily Focus and How to Avoid Them
    12 months ago
    Women’s Demand for Shapewear – the big Trends
    1 year ago
    Valentino Launches its Cosmetics Line
    1 year ago
  8. Business
    McDonald’s Sales Increase Amid COVID Restrictions
    1 year ago
  9. Health
    US Promises to Share 60 million Doses of AstraZeneca Vaccines
    1 year ago
  10. coronavirus
    UK Offers Aid Amid Surging COVID-19 Cases in India
    1 year ago
  11. Entertainment
    Nomadland Director Chloé Zhao, Wins the Best Director in 2021 Oscar
    1 year ago
    Russia ‘plans to take southern Ukraine’ in the Ukraine war
    4 weeks ago
    Girls’ schools in Afghanistan ordered shut just hours after reopening
    2 months ago
    Ukraine: Surrogate mothers and parents face impossible choices
    2 months ago
    Two women killed in Malmö ‘violence’ at a Swedish school
    2 months ago
    Anonymous: How Hackers are Attempting to Destabilize Putin
    2 months ago
    Boris Johnson Sparks Outrage Comparing the Ukraine conflict to Brexit
    2 months ago
    The Big Talk: War crimes and Russia’s invasion of Ukraine
    2 months ago

Follow @rushhourdaily: